ReviewHaematologica2026
Von Willebrand disease: classification and epidemiology.
Review in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Expression of wild-type and recombinant D4-CK domains of VWF gene with novel variants in Pakistan.Molecular biology reports · 2026Article
- Introduction to the Review Series. A century after Erik von Willebrand.Haematologica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Von Willebrand disease (VWD) is a highly heterogeneous inherited bleeding disorder caused by reduced levels or activity of von Willebrand factor (VWF). VWD is associated with a wide spectrum of clinical and laboratory phenotypes, but diagnosis is based on three main criteria: a positive bleeding history, low levels of circulating VWF and autosomal inheritance patterns. VWD is classified into quantitative VWF deficiencies (type 1, partial and type 3, almost total) and peculiar qualitative defects (type 2 A, B, M, and N). The prevalence of VWD has been estimated by epidemiological investigations to be ~1%, but a clearcut diagnosis in clinical practice is often not possible because of several confounding factors influencing plasma VWF levels, especially in mild cases. The prevalence of clinically relevant VWD could range from 1/1,000-10,000 inhabitants based on patients referred to tertiary care centers. Recent genetic prevalence data however suggest that pathogenic VWF variants or putative disease alleles may be significantly more common than 1%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.